Literature DB >> 18420946

A cyclin D2-Rb pathway regulates cardiac myocyte size and RNA polymerase III after biomechanical stress in adult myocardium.

Ekaterini Angelis1, Alejandro Garcia, Shing S Chan, Katja Schenke-Layland, Shuxen Ren, Sarah J Goodfellow, Maria C Jordan, Kenneth P Roos, Robert J White, W Robb MacLellan.   

Abstract

Normally, cell cycle progression is tightly coupled to the accumulation of cell mass; however, the mechanisms whereby proliferation and cell growth are linked are poorly understood. We have identified cyclin (Cyc)D2, a G(1) cyclin implicated in mediating S phase entry, as a potential regulator of hypertrophic growth in adult post mitotic myocardium. To examine the role of CycD2 and its downstream targets, we subjected CycD2-null mice to mechanical stress. Hypertrophic growth in response to transverse aortic constriction was attenuated in CycD2-null compared with wild-type mice. Blocking the increase in CycD2 in response to hypertrophic agonists prevented phosphorylation of CycD2-target Rb (retinoblastoma gene product) in vitro, and mice deficient for Rb had potentiated hypertrophic growth. Hypertrophic growth requires new protein synthesis and transcription of tRNA genes by RNA polymerase (pol) III, which increases with hypertrophic signals. This load-induced increase in RNA pol III activity is augmented in Rb-deficient hearts. Rb binds and represses Brf-1 and TATA box binding protein (TBP), subunits of RNA pol III-specific transcription factor B, in adult myocardium under basal conditions. However, this association is disrupted in response to transverse aortic constriction. RNA pol III activity is unchanged in CycD2(-/-) myocardium after transverse aortic constriction, and there is no dissociation of TBP from Rb. These investigations identify an essential role for the CycD2-Rb pathway as a governor of cardiac myocyte enlargement in response to biomechanical stress and, more fundamentally, as a regulator of the load-induced activation of RNA pol III.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18420946      PMCID: PMC2447867          DOI: 10.1161/CIRCRESAHA.107.163550

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  40 in total

1.  Retinoblastoma protein disrupts interactions required for RNA polymerase III transcription.

Authors:  J E Sutcliffe; T R Brown; S J Allison; P H Scott; R J White
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb.

Authors:  Harold I Saavedra; Lizhao Wu; Alain de Bruin; Cynthia Timmers; Thomas J Rosol; Michael Weinstein; Michael L Robinson; Gustavo Leone
Journal:  Cell Growth Differ       Date:  2002-05

3.  Overexpression of cdk Inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy.

Authors:  T Nozato; H Ito; M Watanabe; Y Ono; S Adachi; H Tanaka; M Hiroe; M Sunamori; F Marum
Journal:  J Mol Cell Cardiol       Date:  2001-08       Impact factor: 5.000

4.  Physical interaction between pRb and cdk9/cyclinT2 complex.

Authors:  Cristiano Simone; Luigi Bagella; Cristiana Bellan; Antonio Giordano
Journal:  Oncogene       Date:  2002-06-13       Impact factor: 9.867

5.  Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis.

Authors:  G Xiao; S Mao; G Baumgarten; J Serrano; M C Jordan; K P Roos; M C Fishbein; W R MacLellan
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

6.  RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors.

Authors:  A G Winter; G Sourvinos; S J Allison; K Tosh; P H Scott; D A Spandidos; R J White
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

7.  The Drosophila cyclin D-Cdk4 complex promotes cellular growth.

Authors:  S A Datar; H W Jacobs; A F de la Cruz; C F Lehner; B A Edgar
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

8.  Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro.

Authors:  Peter K Busk; Jirina Bartkova; Claes C Strøm; Linda Wulf-Andersen; Rebecca Hinrichsen; Tue E H Christoffersen; Lucia Latella; Jiri Bartek; Stig Haunsø; Søren P Sheikh
Journal:  Cardiovasc Res       Date:  2002-10       Impact factor: 10.787

9.  Expression of cyclin D1 and CDK4 causes hypertrophic growth of cardiomyocytes in culture: a possible implication for cardiac hypertrophy.

Authors:  Mimi Tamamori-Adachi; Hiroshi Ito; Kiyoshi Nobori; Kentaro Hayashida; Junya Kawauchi; Susumu Adachi; Masa-Aki Ikeda; Shigetaka Kitajima
Journal:  Biochem Biophys Res Commun       Date:  2002-08-16       Impact factor: 3.575

10.  p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB.

Authors:  Diane Crighton; Annette Woiwode; Cheng Zhang; Nihar Mandavia; Jennifer P Morton; Lorna J Warnock; Jo Milner; Robert J White; Deborah L Johnson
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

View more
  17 in total

1.  The role of E2F-1 and downstream target genes in mediating ischemia/reperfusion injury in vivo.

Authors:  Ekaterini Angelis; Peng Zhao; Rui Zhang; Joshua I Goldhaber; W Robb Maclellan
Journal:  J Mol Cell Cardiol       Date:  2011-09-22       Impact factor: 5.000

2.  Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7.

Authors:  Yanfei Yang; Tetsuro Ago; Peiyong Zhai; Maha Abdellatif; Junichi Sadoshima
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

3.  Cardiac myocyte p38α kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart.

Authors:  Beth A Rose; Tomohiro Yokota; Vishnu Chintalgattu; Shuxun Ren; Luisa Iruela-Arispe; Aarif Y Khakoo; Susumu Minamisawa; Yibin Wang
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

4.  Cardiomyocyte proliferation prevents failure in pressure overload but not volume overload.

Authors:  Karl Toischer; Wuqiang Zhu; Mark Hünlich; Belal A Mohamed; Sara Khadjeh; Sean P Reuter; Katrin Schäfer; Deepak Ramanujam; Stefan Engelhardt; Loren J Field; Gerd Hasenfuss
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

5.  Regulation of TFIIIB during F9 cell differentiation.

Authors:  Dimitris Athineos; Lynne Marshall; Robert J White
Journal:  BMC Mol Biol       Date:  2010-03-12       Impact factor: 2.946

6.  Propranolol enhances cell cycle-related gene expression in pressure overloaded hearts.

Authors:  Marco Musumeci; Sonia Maccari; Paola Sestili; Michele Signore; Paola Molinari; Caterina Ambrosio; Tonino Stati; William H Colledge; Andrew A Grace; Liviana Catalano; Giuseppe Marano
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

7.  Effect of different resistance-training regimens on the WNT-signaling pathway.

Authors:  Marcelo Larciprete Leal; Leonardo Lamas; Marcelo Saldanha Aoki; Carlos Ugrinowitsch; Marcela Sorelli Carneiro Ramos; Valmor Tricoli; Anselmo Sigari Moriscot
Journal:  Eur J Appl Physiol       Date:  2011-03-02       Impact factor: 3.078

8.  Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes.

Authors:  Marc-Michael Zaruba; Wuqiang Zhu; Mark H Soonpaa; Sean Reuter; Wolfgang-Michael Franz; Loren J Field
Journal:  Eur Heart J       Date:  2011-08-17       Impact factor: 29.983

9.  Cyclin D2 is a critical mediator of exercise-induced cardiac hypertrophy.

Authors:  Stephen W Luckey; Chris D Haines; John P Konhilas; Elizabeth D Luczak; Antke Messmer-Kratzsch; Leslie A Leinwand
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-13

10.  Cyclin D2 rescues size and function of GATA4 haplo-insufficient hearts.

Authors:  Abir Yamak; Rana Temsah; Wael Maharsy; Sophie Caron; Pierre Paradis; Anne Aries; Mona Nemer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.